First Trust Value Line Dividend Index Fund

Most Recent

  • uploads///Part  Dividend Institutional Investors Q
    Company & Industry Overviews

    Stanley Black & Decker: Institutional Holdings

    The 13F filings on September 30 indicated that institutional investors own ~87.9% of Stanley Black & Decker’s (SWK) outstanding shares.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Sanofi: Analysts’ Recommendations on October 30

    As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”

    By Mike Benson
  • uploads///drug _
    Earnings Report

    GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates

    Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Novartis’s Sandoz Performed in the Third Quarter

    Novartis’s (NVS) Sandoz is a market leader in differentiated generics.

    By Mike Benson
  • uploads///test _
    Earnings Report

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis released its third-quarter earnings results on October 18. Let’s see how it performed compared to analysts’ consensus estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Sandoz Business Has Been Performing Recently

    Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Pharmaceutical Business Performed

    GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.

    By Mike Benson
  • uploads///management _
    Company & Industry Overviews

    Alcon to Set Up Future Global Headquarters in Geneva

    Alcon, the eyecare business of Novartis (NVS), includes surgical products and vision care products. It announced today that it will locate its future headquarters in Geneva after spinning off from Novartis.

    By Mike Benson
  • uploads///eye _
    Company & Industry Overviews

    Alcon Voluntarily Withdraws CyPass Micro-Stent from Global Market

    On August 29, Alcon announced that it had voluntarily withdrawn the CyPass Micro-Stent on a global basis, effective immediately.

    By Mike Benson
  • uploads///medic _
    Company & Industry Overviews

    EC Approves Amgen’s Blincyto for Pediatric Patients

    Today, Amgen (AMGN) announced EC approval of Blincyto for pediatric patients with Philadelphia chromosome-negative CD19 positive refractory.

    By Mike Benson
  • uploads///microbiology _
    Company & Industry Overviews

    European Commission Approves Novartis’s Tafinlar/Mekinist Combo

    Novartis (NVS) announced on August 29 that the European Commission had approved the combination of its drugs Tafinlar and Mekinist.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Business Segments in Q2 2018

    Sandoz, Novartis’s generic pharmaceuticals business, reported nearly flat revenues at ~$2.46 billion in Q2 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Novartis’s Valuation after Its Q2 2018 Earnings

    On July 20, Novartis was trading at a forward PE multiple of ~15.0x. The industry currently trades at a forward PE multiple of ~14.1x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Why GlaxoSmithKline’s Q2 2018 Revenues Are Expected to Decline

    The Pharmaceuticals segment is expected to report growth in operating revenues in Q2 2018 with a strong performance of new respiratory products.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    GlaxoSmithKline’s Valuation on June 29

    In the first quarter, GlaxoSmithKline reported EPS of 24.60 pence on revenue of 7.2 billion pounds, a 2% fall year-over-year.

    By Mike Benson
  • uploads///AVB RENT EPS
    Real Estate

    AvalonBay: What’s Driving the Dividend and Valuations?

    AvalonBay’s revenue grew 7% in the first quarter, driven by rental and other income.

    By Amanda Lawrence
  • uploads///healthcre
    Healthcare

    How the Healthcare Sector’s Dividend Yield Stacks Up

    The healthcare industry has an average dividend yield of 1.9%.

    By Amanda Lawrence
  • uploads///Chart
    Company & Industry Overviews

    Assessing GlaxoSmithKline’s Quarterly Revenues

    GlaxoSmithKline (GSK) reported a 4% rise in operating revenue to ~7.2 billion British pounds in Q1 2018 compared to ~7.3 billion pounds in Q1 2017.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    How Novartis’s Valuation Compares

    This year, Switzerland-headquartered biopharmaceutical giant Novartis (NVS) has initiated several medical data and digital technology deals.

    By Mike Benson
  • uploads///hands _
    Healthcare

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis completed the acquisition of AveXis, which strengthens Novartis’s position as a gene therapy and neuroscience leader.

    By Mike Benson
  • uploads///dna
    Earnings Report

    GlaxoSmithKline’s 1Q18 Earnings: Revenue Trend

    GlaxoSmithKline (GSK) reported revenues of ~7.2 billion pounds for 1Q18 on April 25.

    By Mike Benson
  • uploads///optometrist _
    Company & Industry Overviews

    Novartis Launches FocalView to Modernize Clinical Trials

    On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

    By Mike Benson
  • uploads///Chart  Rev
    Earnings Report

    Sanofi’s 1Q18: Revenue Expected to Fall

    Sanofi’s 1Q18 revenue estimates As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations. Structure of the group The above graph shows Sanofi’s revenue since 1Q17 and estimates for 1Q18. In 2016, Sanofi reorganized its businesses into five units: Sanofi Genzyme, its specialty care business, which […]

    By Mike Benson
  • uploads///headache _
    Earnings Report

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline is set to release its 1Q18 earnings on April 25, 2018.

    By Mike Benson
  • uploads///microbiology _
    Earnings Report

    Expectations from Novartis’s 1Q18 Earnings

    Novartis is set to release its 1Q18 earnings on April 19, 2018. Analysts expect it to report earnings per share of $1.28.

    By Mike Benson
  • uploads///Chart
    Healthcare

    Novartis’s Stock Performance following the AveXis Agreement

    Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Oncology Products Performed in 4Q17

    Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the oncology products Alimta, Cyramza, Erbitux, Gemzar, Lartruvo, Portrazza, and Verzenio.

    By Mike Benson
  • uploads///hands _
    Healthcare

    How Merck Stock Has Performed Recently

    Merck stock has fallen ~2.0% over the last one month and ~14.9% over the last one year.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Novartis’s Revenues Trended in 4Q17

    Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Analyst Recommendations for Johnson & Johnson in February 2018

    Analysts estimate that the stock could rise ~13.8% over the next 12 months. They have a 12-month target price of $150.62 for JNJ.

    By Mike Benson
  • uploads///div pri so
    Energy & Utilities

    These Factors Could Drive SO’s Dividend Growth

    Southern Company’s (SO) present dividend yield of 5.4% has been driven by dividend growth and a price loss.

    By Amanda Lawrence
  • uploads///pill _
    Earnings Report

    Sanofi’s Quarterly Revenue Trend in 4Q17

    Sanofi (SNY) reported revenues of 8.7 billion euros in 4Q17, an ~2.0% decrease compared to revenues of 8.9 billion euros in 4Q16.

    By Mike Benson
  • uploads///ablynx sanofi partnership
    Company & Industry Overviews

    A Look at Ablynx and Sanofi’s Existing Partnership

    On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q17 Revenues and Fiscal 2017 Revenues

    Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17 compared to ~$12.3 billion in 4Q16. NVS reported 2.0% growth in operating revenues in 4Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Is Focused on Developing Oncology Asset GSK 916

    According to Kantar Health and Decision Resources, multiple myeloma (or MM) accounts for around 15% of the hematological malignancies in the world and ranks second in terms of incidence among the various blood cancers after non-Hodgkin’s lymphoma.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline

    Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).

    By Margaret Patrick
  • uploads///Tafinlar
    Company & Industry Overviews

    How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Tafinlar+Mekinist reported revenues of $187 million, $216 million, and $224 million, respectively.

    By Daniel Collins
  • uploads///div pri gro aiz
    Financials

    Why Assurant Has a Positive Outlook despite a Weak 2017

    Assurant’s (AIZ) revenue fell 27% and 18% in 2016 and 9M17, respectively.

    By Amanda Lawrence
  • uploads///Chart
    Company & Industry Overviews

    Reading Sanofi’s End-of-Year Analyst Estimates

    Wall Street analysts estimate that Sanofi will report EPS of 5.60 euros for 2017, compared with its EPS of 5.68 euros in 2016.

    By Mike Benson
  • uploads///Gleevec
    Company & Industry Overviews

    Behind 4 Key Novartis Money Makers (and Losers) in 3Q17

    In 3Q17, Novartis’s (NVS) Gleevec generated revenues of $445 million, which was ~47% lower YoY (year-over-year) and ~12% lower QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///Respiratory
    Company & Industry Overviews

    Behind Novartis’s Respiratory Drug Performance in 3Q17

    In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.

    By Daniel Collins
  • uploads///REV EPS AIZ
    Financials

    A Look at Assurant, Another Top Dividend Grower

    Assurant’s revenue and earnings in 2015 and 2016 Assurant’s (AIZ) revenue fell 1% and 27% in 2015 and 2016, respectively. Its US revenue rose in 2015 before falling in 2016, and its international revenue fell in both years, along with its net earned premiums, net investment income, and net realized gains on investments. Its fees and other […]

    By Amanda Lawrence
  • uploads///AD
    Miscellaneous

    How Do Aerospace and Defense Sector Dividends Look?

    This series will discuss the top ten aerospace and defense products and services companies based on their dividend yields.

    By Amanda Lawrence
  • uploads///SALES EPS GWW
    Industrials

    What Changed W.W. Grainger’s Dividend Yield Graph?

    W.W. Grainger (GWW) recorded a 2.0% net sales growth in 2016 after flat growth in 2015.

    By Amanda Lawrence
  • uploads///Graph
    Company & Industry Overviews

    Sanofi’s Consumer Healthcare Expected to Be Long-Term Driver

    In 2Q17, Sanofi’s (SNY) Consumer Healthcare business reported revenues of 1.2 billion euros, which is a 42.5% YoY rise on a CER basis and a YoY fall of 0.10% on a CER and CS basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis

    Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Behind Sanofi’s Established Product Performance in 3Q17

    For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.

    By Mike Benson
  • uploads///Chart  Vac
    Company & Industry Overviews

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

    By Mike Benson
  • uploads///SRE
    Energy & Utilities

    What Led to Sempra Energy’s Sharp Fall in Dividend Yield?

    Sempra Energy’s revenue for the first half of 2017 rose 7.0%, driven by every segment.

    By Amanda Lawrence
  • uploads///Promacta Votrient jakavi
    Company & Industry Overviews

    How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

    In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Novartis in September 2017

    Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”

    By Daniel Collins
  • uploads///FTI PRICE
    Miscellaneous

    What Could Drive TechnipFMC’s Dividend Yield

    How TechnipFMC intends to maintain its yield FMC Technologies and Technip merged to become TechnipFMC (FTI) in 2017, an international provider of subsea, onshore, offshore, and surface projects. The synergy aims to combat the challenges of low oil prices and a challenging outlook through cost cutting and the enhancement of efficiency. The company recorded 51% revenue […]

    By Amanda Lawrence
  • uploads///Chart  Rev
    Company & Industry Overviews

    GlaxoSmithKline Reported Revenue Growth in 2Q17

    GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.

    By Mike Benson
  • uploads///Chart  Segment
    Company & Industry Overviews

    Inside Novartis’s 2Q17 Revenues

    Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Bristol-Myers Squibb’s Valuation after 2Q17 Earnings

    Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.

    By Mike Benson
  • uploads///DY BEN
    Financials

    Dividend Yield of Franklin Resources

    Franklin Resources (BEN) has recorded consistent growth in dividends since at least March 1982.

    By Amanda Lawrence
  • uploads///Chart  GCHC
    Company & Industry Overviews

    Sanofi’s General Medicines and Consumer Healthcare in 2Q17

    General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […]

    By Mike Benson
  • uploads///Chart  Val
    Company & Industry Overviews

    A Look at Sanofi’s Post-2Q17 Valuation

    Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.

    By Mike Benson
  • uploads///TGTVS
    Consumer

    Target’ s Performance as a Dividend Aristocrat

    Target’s (TGT) sales for 2016 fell 6.0% due to lower comparable store sales and weak store traffic.

    By Amanda Lawrence
  • uploads///INTC
    Consumer

    Have Intel and Procter & Gamble Been Able to Increase Dividends?

    Intel (INTC) released its 2Q17 results on July 27, 2017. The company’s revenue and EPS for the first half of 2017 rose 8.5% and 72.0%, respectively.

    By Amanda Lawrence
  • uploads///Chart  Pharma
    Earnings Report

    GSK’s 2Q17 Earnings: Pharmaceuticals Segment

    GSK’s Pharmaceuticals segment’s contribution to the company’s total revenues was 59.5% in 2Q17.

    By Mike Benson
  • uploads///ABR
    Financials

    Arbor Realty Trust’s Dividend Growth Prospects

    Arbor Realty Trust (ABR) paid 74.1% of its earnings as dividends in 2016 compared to 56.7% in 1Q17.

    By Amanda Lawrence
  • uploads///Chart  Revenue
    Earnings Report

    Unpacking GlaxoSmithKline’s 2Q17 Revenue Expectations

    Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.

    By Mike Benson
  • uploads///Chart  Inno
    Earnings Report

    Novartis in 2Q17: Performance of Innovative Medicines

    The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Novartis’s 2Q17 Estimates: Innovative Medicines Segment

    The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.

    By Mike Benson
  • uploads///abbv
    Miscellaneous

    The Top Dividend-Growing Healthcare and Industrials Stocks

    The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms.

    By Amanda Lawrence
  • uploads///QCOM
    Miscellaneous

    Dividend Growth for Qualcomm and Crown Castle International

    Qualcomm (QCOM) recorded a year-over-year decline in revenues for 2Q17 after growth in the preceding quarter.

    By Amanda Lawrence
  • uploads///Chart  EPS
    Company & Industry Overviews

    What Happened to Novartis’s Valuation after 1Q17?

    Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues.

    By Mike Benson
  • uploads///Chart  GCHC
    Company & Industry Overviews

    Sanofi’s Generics and Consumer Healthcare Business in 1Q17

    Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.

    By Mike Benson
  • uploads///Chart  Inno Medicines
    Earnings Report

    Novartis’s 1Q17 Estimates: Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters

    Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Are Sanofi’s Established Prescription Products Adding Up?

    Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Sanofi’s Overall Revenue Performance in 2016

    Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Could Novartis’s CTL019 Capture Significant Market Share?

    Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis Expects to Witness Flat Revenue Growth in 2017

    Novartis (NVS) has projected its 2017 revenue to be close to what it earned in 2016. The company also expects its core operating income to be flat or to fall in the single digits.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Entresto Could Become Key Growth Driver for Novartis in 2017

    Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Valuation Compared to Its Peers’

    Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Will Drive AstraZeneca’s Oncology Revenues in 2017?

    In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s New Products May Offer 2017 Growth Opportunities

    Since 2012, AstraZeneca (AZN) has launched new products in its three main therapeutic areas of diabetes and respiratory diseases, cardiovascular diseases, and oncology.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Growth of AstraZeneca’s Oncology Segment in 2016

    The revenues for AstraZeneca’s (AZN) Oncology segment rose ~20% at constant exchange rates in 2016.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    These Prescription Products Matter to Sanofi’s Growth

    Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Novartis’s Valuation after the 4Q16 Results

    On January 31, 2017, Novartis was trading at a forward PE multiple of ~15.2x. Based on its last-five-year multiple range, this is neither high nor low.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Generics Performance in 4Q16

    Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Expect Negative Growth for Novartis in 4Q16

    Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Did Novartis’s Innovative Medicines Segment Perform?

    The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016

    On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s Research Pipeline to Culminate in Many New Drug Launches?

    Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug

    On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics

    In 3Q16, Teva Pharmaceutical Industries (TEVA) reported increased price erosion of about 7.0% for its US-based business compared to 3Q15.

    By Margaret Patrick
  • uploads///Fund Flows
    Company & Industry Overviews

    Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’

    In his November Insights newsletter, Richard Bernstein stated, “It is incredible that investors have basically been wallflowers during the second longest bull market of the post-war period.”

    By David Ashworth
  • uploads///Chart
    Company & Industry Overviews

    Performance of Novartis’s Innovative Medicines Segment in 3Q16

    Novartis’s (NVS) Innovative Medicines segment contributed ~67.0% at $8.2 billion for 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Changes in Novartis’s Valuation for 3Q16

    Based on the last five years’ multiple range, Novartis’s current valuation is neither high nor low. The PE multiple has ranged from ~9.0x to ~20.0x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside AstraZeneca’s Oncology Segment Growth in 3Q15

    AstraZeneca’s (AZN) Oncology segment is another key company focus area. The segment’s contribution rose to over 17% in 3Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Inside AstraZeneca’s Revenue Fall in 3Q16

    For 3Q16, AstraZeneca (AZN) reported a 4.1% fall in its top line at $5.7 billion.

    By Mike Benson
  • uploads///SP  Sector Returns in YTD
    Company & Industry Overviews

    Richard Bernstein: Don’t Fear the Bear Market

    A legitimate bull market In this series, we’ve taken a look at Richard Bernstein’s views on investors’ fear of an impending bear market. In Richard Bernstein Advisors’ October Insights newsletter, he rejects the notion that the current rise in US stocks (SPLV) (OEF) has been brought about only by the Fed’s easy monetary policy. In the […]

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Volume Growth and Product Mix to Drive NVO’s Insulin Sales

    From 2011 to 2015, Novo Nordisk’s (NVO) diabetes care franchise sales have risen at a compounded average growth rate (or CAGR) of approximately 11.5%.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.